Rights and permissions
About this article
Cite this article
CD4+ cell count dominant prognostic factor in patients starting HAART. Inpharma Wkly. 1347, 8 (2002). https://doi.org/10.2165/00128413-200213470-00019
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-200213470-00019